Volume 2,
Number 3

HIV SURVEILLANCE DATA TABLES

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative *(Preliminary Data)*:

National HIV Surveillance System Data Reported through March 2021; and Preexposure Prophylaxis (PrEP) Data Reported through December 2020

Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through March 2021 and preexposure prophylaxis (PrEP) data reported through December 2020.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and preexposure prophylaxis (PrEP) data reported through December 2020. *HIV Surveillance Data Tables* 2021;2(No. 3). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published July 2021. Accessed [date].

On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Jianmin Li, Xiaohong Hu, Baohua Wu, Kyung Lee, Weiming Zhu, Lei Yu, Saja Khader, Tameka Hayes, and Norma Harris.

Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for editing and desktop publishing this report.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Contents

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-1/index.html.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of March 2021 for the years 2020 and 2021, and data on preexposure prophylaxis (PrEP) coverage for the years 2019 and 2020 (preliminary). Data for the 3 indicators are provided at the national-, state-, and county-levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

Tabulation and Presentation of Data

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years with HIV diagnosed during January 2020 through March 2021 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2011–2015 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-32/index.html (*HIV Surveillance Report, 2019*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose infection was diagnosed during 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed during 2020 and who had ≥1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during 2020. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during 2020 and that were reported to NHSS through March 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions [2].

More information on calculating linkage to care can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-26-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019*).

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 3a–3c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include white, black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S Department of Housing and Urban Development's ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [8, 9]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [10].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the year 2019 and data for the year 2020 by using the IQVIA data reported through December 2020. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indica-

tions for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019 and 2020 PrEP coverage data; consequently, 2019 and 2020 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

More information on calculating PrEP coverage can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-26-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019*).

REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Updated June 2, 2021. Accessed June 30, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2
3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
6. U.S. Census Bureau. American Community Survey 5-year data (2009–2018). https://www.census.gov/data/developers/data-sets/acs-5year.2018.html. Published December 19, 2019. Accessed June 30, 2021.
7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Published 2019. Accessed June 30, 2021.
8. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14.
9. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107.
10. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through March 2021—United States *(preliminary)*

	2020 No.	2021 (January–March) No.
Gender		
Male	22,514	3,723
Female	5,041	817
Transgender male-to-female[a]	541	69
Transgender female-to-male[a]	35	6
Additional gender identity[b]	10	3
Age at diagnosis (yr)		
13–24	5,617	885
25–34	10,386	1,680
35–44	5,494	953
45–54	3,683	591
≥55	2,961	509
Race/ethnicity		
American Indian/Alaska Native	184	25
Asian	581	111
Black/African American	12,219	2,046
Hispanic/Latino[c]	7,199	1,088
Native Hawaiian/other Pacific Islander	58	13
White	7,350	1,287
Multiracial	550	48
Transmission category[d]		
Male-to-male sexual contact	19,131	3,194
Injection drug use		
Male	1,105	161
Female	774	127
Male-to-male sexual contact and injection drug use	972	151
Heterosexual contact[e]		
Male	1,827	282
Female	4,278	693
Other[f]		
Male	30	7
Female	25	4
Region of residence[g]		
Northeast	4,020	525
Midwest	3,748	552
South	14,814	2,806
West	5,559	735
Total	**28,141**	**4,618**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2020 through March 2021—United States and 6 dependent areas *(preliminary)*

	2020 No.	2021 (January–March) No.
Gender		
Male	22,750	3,770
Female	5,082	827
Transgender male-to-female[a]	543	69
Transgender female-to-male[a]	35	6
Additional gender identity[b]	10	3
Age at diagnosis (yr)		
13–24	5,664	893
25–34	10,464	1,699
35–44	5,554	964
45–54	3,731	604
≥55	3,007	515
Race/ethnicity		
American Indian/Alaska Native	184	25
Asian	581	111
Black/African American	12,221	2,047
Hispanic/Latino[c]	7,474	1,143
Native Hawaiian/other Pacific Islander	58	13
White	7,352	1,288
Multiracial	550	48
Transmission category[d]		
Male-to-male sexual contact	19,306	3,232
Injection drug use		
Male	1,125	164
Female	776	127
Male-to-male sexual contact and injection drug use	978	151
Heterosexual contact[e]		
Male	1,865	288
Female	4,316	703
Other[f]		
Male	30	7
Female	25	4
Region of residence[g]		
Northeast	4,020	525
Midwest	3,748	552
South	14,814	2,806
West	5,559	735
U.S. dependent areas	279	57
Total	**28,420**	**4,675**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through March 2021—United States and 6 dependent areas *(preliminary)*

Area of residence	2020 No.	2021 (January–March) No.
Alabama	578	24
Alaska	29	2
Arizona	687	76
Arkansas	247	54
California	3,270	388
Colorado	309	62
Connecticut	153	18
Delaware	97	21
District of Columbia	205	31
Florida	3,569	962
Georgia	1,699	251
Hawaii	43	2
Idaho	29	0
Illinois	777	96
Indiana	431	63
Iowa	99	21
Kansas	139	25
Kentucky	293	64
Louisiana	742	205
Maine	17	4
Maryland	722	113
Massachusetts	373	22
Michigan	532	105
Minnesota	221	59
Mississippi	380	52
Missouri	361	95
Montana	14	2
Nebraska	67	3
Nevada	372	60
New Hampshire	29	2
New Jersey	733	77
New Mexico	69	10
New York	1,894	255
North Carolina	1,088	276
North Dakota	23	1
Ohio	855	37
Oklahoma	208	30
Oregon	178	40
Pennsylvania	765	146
Rhode Island	49	1
South Carolina	727	160
South Dakota	34	6
Tennessee	638	136
Texas	2,877	238
Utah	129	22
Vermont	7	0
Virginia	623	178
Washington	416	70
West Virginia	121	11
Wisconsin	209	41
Wyoming	14	1
Subtotal	28,141	4,618
U.S. dependent areas		
American Samoa	0	0
Guam	0	1
Northern Mariana Islands	0	0
Puerto Rico	277	56
Republic of Palau	0	0
U.S. Virgin Islands	2	0
Subtotal	279	57
Total	**28,420**	**4,675**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through March 2021—Ending the HIV Epidemic Phase I jurisdictions *(preliminary)*

Area of residence	2020 No.	2021 (January–March) No.
Arizona		
Maricopa County	491	61
California		
Alameda County	149	24
Los Angeles County	1,145	132
Orange County	261	48
Riverside County	228	33
Sacramento County	24	1
San Bernardino County	214	16
San Diego County	249	5
San Francisco County	152	26
District of Columbia	205	31
Florida		
Broward County	489	124
Duval County	236	70
Hillsborough County	259	68
Miami-Dade County	834	235
Orange County	398	98
Palm Beach County	227	46
Pinellas County	158	45
Georgia		
Cobb County	126	12
DeKalb County	226	37
Fulton County	481	67
Gwinnett County	111	15
Illinois		
Cook County	592	72
Indiana		
Marion County	168	30
Louisiana		
East Baton Rouge Parish	127	25
Orleans Parish	109	45
Maryland		
Baltimore City	171	21
Montgomery County	87	21
Prince George's County	212	31
Massachusetts		
Suffolk County	119	9
Michigan		
Wayne County	228	50
Nevada		
Clark County	323	53
New Jersey		
Essex County	183	26
Hudson County	118	9

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2020 through March 2021—Ending the HIV Epidemic Phase I jurisdictions *(preliminary) (cont)*

Area of residence	2020 No.	2021 (January–March) No.
New York		
Bronx County	334	37
Kings County	426	58
New York County	289	34
Queens County	306	27
North Carolina		
Mecklenburg County	210	66
Ohio		
Cuyahoga County	184	8
Franklin County	199	14
Hamilton County	128	1
Pennsylvania		
Philadelphia County	321	54
Puerto Rico		
San Juan Municipio	68	17
Tennessee		
Shelby County	223	45
Texas		
Bexar County	283	22
Dallas County	608	68
Harris County	647	20
Tarrant County	231	10
Travis County	157	26
Washington		
King County	202	34

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis during 2020 among persons aged ≥13 years, by selected characteristics—44 states and the District of Columbia *(preliminary)*

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Gender					
Male	20,960	17,262	82.4	3,698	17.6
Female	4,666	3,823	81.9	843	18.1
Transgender male-to-female[a]	508	413	81.3	95	18.7
Transgender female-to-male[a]	32	30	93.8	2	6.3
Additional gender identity[b]	9	8	88.9	1	11.1
Age at diagnosis (yr)					
13–24	5,257	4,215	80.2	1,042	19.8
25–34	9,676	7,916	81.8	1,760	18.2
35–44	5,108	4,198	82.2	910	17.8
45–54	3,391	2,895	85.4	496	14.6
≥55	2,743	2,312	84.3	431	15.7
Race/ethnicity					
American Indian/Alaska Native	179	145	81.0	34	19.0
Asian	557	491	88.2	66	11.8
Black/African American	11,434	9,135	79.9	2,299	20.1
Hispanic/Latino[c]	6,717	5,658	84.2	1,059	15.8
Native Hawaiian/other Pacific Islander	57	49	86.0	8	14.0
White	6,726	5,633	83.7	1,093	16.3
Multiracial	505	425	84.2	80	15.8
Transmission category[d]					
Male-to-male sexual contact	17,946	14,839	82.7	3,106	17.3
Injection drug use	1,673	1,321	79.0	353	21.1
Male	963	760	78.9	204	21.1
Female	710	561	79.0	149	21.0
Male-to-male sexual contact and injection drug use	898	726	80.9	171	19.1
Heterosexual contact[e]	5,607	4,606	82.1	1,001	17.9
Male	1,643	1,336	81.3	307	18.7
Female	3,964	3,270	82.5	694	17.5
Total[f]	**26,175**	**21,536**	**82.3**	**4,639**	**17.7**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during 2020 and reported to NHSS through March 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis during 2020 among persons aged ≥13 years, by area of residence—44 states and the District of Columbia *(preliminary)*

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Alabama	578	465	80.4	113	19.6
Alaska	29	28	96.6	1	3.4
Arizona	687	583	84.9	104	15.1
Arkansas	247	210	85.0	37	15.0
California	3,270	2,767	84.6	503	15.4
Colorado	309	271	87.7	38	12.3
Connecticut	153	132	86.3	21	13.7
Delaware	97	78	80.4	19	19.6
District of Columbia	205	180	87.8	25	12.2
Florida	3,569	3,001	84.1	568	15.9
Georgia	1,699	1,446	85.1	253	14.9
Hawaii	43	38	88.4	5	11.6
Illinois	777	656	84.4	121	15.6
Indiana	431	313	72.6	118	27.4
Iowa	99	88	88.9	11	11.1
Louisiana	742	565	76.1	177	23.9
Maine	17	16	94.1	1	5.9
Maryland	722	638	88.4	84	11.6
Massachusetts	373	324	86.9	49	13.1
Michigan	532	446	83.8	86	16.2
Minnesota	221	194	87.8	27	12.2
Mississippi	380	278	73.2	102	26.8
Missouri	361	284	78.7	77	21.3
Montana	14	12	85.7	2	14.3
Nebraska	67	61	91.0	6	9.0
Nevada	372	318	85.5	54	14.5
New Hampshire	29	23	79.3	6	20.7
New Mexico	69	57	82.6	12	17.4
New York	1,894	1,634	86.3	260	13.7
North Carolina	1,088	897	82.4	191	17.6
North Dakota	23	18	78.3	5	21.7
Ohio	855	748	87.5	107	12.5
Oklahoma	208	160	76.9	48	23.1
Oregon	178	151	84.8	27	15.2
Rhode Island	49	45	91.8	4	8.2
South Carolina	727	640	88.0	87	12.0
South Dakota	34	30	88.2	4	11.8
Tennessee	638	471	73.8	167	26.2
Texas	2,877	1,989	69.1	888	30.9
Utah	129	112	86.8	17	13.2
Virginia	623	509	81.7	114	18.3
Washington	416	371	89.2	45	10.8
West Virginia	121	91	75.2	30	24.8
Wisconsin	209	185	88.5	24	11.5
Wyoming	14	13	92.9	1	7.1
Total	**26,175**	**21,536**	**82.3**	**4,639**	**17.7**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during 2020 and reported to NHSS through March 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(preliminary)*

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Arizona					
Maricopa County	491	419	85.3	72	14.7
California					
Alameda County	149	127	85.2	22	14.8
Los Angeles County	1,145	963	84.1	182	15.9
Orange County	261	235	90.0	26	10.0
Riverside County	228	188	82.5	40	17.5
Sacramento County	24	20	83.3	4	16.7
San Bernardino County	214	157	73.4	57	26.6
San Diego County	249	218	87.6	31	12.4
San Francisco County	152	144	94.7	8	5.3
District of Columbia	205	180	87.8	25	12.2
Florida					
Broward County	489	426	87.1	63	12.9
Duval County	236	190	80.5	46	19.5
Hillsborough County	259	220	84.9	39	15.1
Miami-Dade County	834	700	83.9	134	16.1
Orange County	398	336	84.4	62	15.6
Palm Beach County	227	183	80.6	44	19.4
Pinellas County	158	132	83.5	26	16.5
Georgia					
Cobb County	126	111	88.1	15	11.9
DeKalb County	226	196	86.7	30	13.3
Fulton County	481	419	87.1	62	12.9
Gwinnett County	111	88	79.3	23	20.7
Illinois					
Cook County	592	498	84.1	94	15.9
Indiana					
Marion County	168	124	73.8	44	26.2
Louisiana					
East Baton Rouge Parish	127	103	81.1	24	18.9
Orleans Parish	109	86	78.9	23	21.1
Maryland					
Baltimore City	171	149	87.1	22	12.9
Montgomery County	87	77	88.5	10	11.5
Prince George's County	212	192	90.6	20	9.4
Massachusetts					
Suffolk County	119	106	89.1	13	10.9
Michigan					
Wayne County	228	188	82.5	40	17.5
Nevada					
Clark County	323	276	85.4	47	14.6
New York					
Bronx County	334	286	85.6	48	14.4
Kings County	426	359	84.3	67	15.7
New York County	289	248	85.8	41	14.2
Queens County	306	272	88.9	34	11.1

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(preliminary) (cont)*

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
North Carolina					
Mecklenburg County	210	175	83.3	35	16.7
Ohio					
Cuyahoga County	184	168	91.3	16	8.7
Franklin County	199	178	89.4	21	10.6
Hamilton County	128	114	89.1	14	10.9
Pennsylvania					
Philadelphia County	321	280	87.2	41	12.8
Tennessee					
Shelby County	223	149	66.8	74	33.2
Texas					
Bexar County	283	171	60.4	112	39.6
Dallas County	608	420	69.1	188	30.9
Harris County	647	460	71.1	187	28.9
Tarrant County	231	148	64.1	83	35.9
Travis County	157	105	66.9	52	33.1
Washington					
King County	202	182	90.1	20	9.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2021, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during 2020 and reported to NHSS through March 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kansas, Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by selected characteristics—United States

	Persons prescribed PrEP[a]	Persons with PrEP indications[b]	PrEP coverage[c]
	No.	No.	%
	2019		
Sex at birth			
Male	248,106	989,200	25.1
Female	20,856	227,010	9.2
Age (yr)			
16–24	37,244	246,290	15.1
25–34	109,593	434,680	25.2
35–44	62,374	238,470	26.2
45–54	36,273	173,420	20.9
≥55	23,538	123,350	19.1
Race/ethnicity[d]			
Black/African American	36,578	468,540	7.8
Hispanic/Latino[e]	42,270	312,820	13.5
Other	11,423	131,180	8.7
White	178,834	300,650	59.5
Total	**269,106**	**1,216,210**	**22.1**
	2020		
Sex at birth			
Male	257,141	989,200	26.0
Female	21,872	227,010	9.6
Age (yr)			
16–24	34,452	246,290	14.0
25–34	111,444	434,680	25.6
35–44	66,804	238,470	28.0
45–54	37,845	173,420	21.8
≥55	28,489	123,350	23.1
Race/ethnicity[d]			
Black/African American	39,499	468,540	8.4
Hispanic/Latino[e]	45,648	312,820	14.6
Other	11,357	131,180	8.7
White	182,626	300,650	60.7
Total	**279,130**	**1,216,210**	**23.0**

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for year 2020 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated using data from IQVIA pharmacy database reported through December 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

[e] Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Alabama	1,826	11,020	16.6
Alaska	228	1,780	12.8
Arizona	4,468	25,780	17.3
Arkansas	731	5,130	14.2
California	40,844	165,030	24.7
Colorado	4,223	25,120	16.8
Connecticut	2,625	9,560	27.5
Delaware	460	4,400	10.5
District of Columbia	5,701	12,950	44.0
Florida	21,479	125,330	17.1
Georgia	8,427	39,030	21.6
Hawaii	806	4,360	18.5
Idaho	450	4,790	9.4
Illinois	16,368	55,860	29.3
Indiana	2,915	22,170	13.1
Iowa	1,385	4,760	29.1
Kansas	892	5,060	17.6
Kentucky	1,568	12,990	12.1
Louisiana	3,881	15,920	24.4
Maine	624	3,950	15.8
Maryland	4,867	27,300	17.8
Massachusetts	9,113	24,900	36.6
Michigan	4,312	29,570	14.6
Minnesota	4,106	21,720	18.9
Mississippi	927	4,530	20.5
Missouri	3,387	18,370	18.4
Montana	261	2,290	11.4
Nebraska	601	2,180	27.6
Nevada	2,124	11,390	18.6
New Hampshire	597	3,020	19.8
New Jersey	5,572	25,280	22.0
New Mexico	1,061	6,800	15.6
New York	34,321	72,640	47.2
North Carolina	5,288	32,490	16.3
North Dakota	194	1,520	12.8
Ohio	5,986	40,320	14.8
Oklahoma	1,133	11,030	10.3
Oregon	3,289	19,750	16.7
Pennsylvania	9,950	36,490	27.3
Puerto Rico	327	9,700	3.4
Rhode Island	1,053	3,880	27.1
South Carolina	1,701	10,390	16.4
South Dakota	144	910	15.8
Tennessee	3,814	22,460	17.0
Texas	22,754	123,790	18.4
Utah	1,983	6,840	29.0
Vermont	335	1,060	31.6
Virginia	4,329	31,430	13.8
Washington	9,441	40,050	23.6
West Virginia	563	5,250	10.7
Wisconsin	2,415	12,980	18.6
Wyoming	93	890	10.4

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2020	
Alabama	1,840	11,020	16.7
Alaska	216	1,780	12.1
Arizona	4,707	25,780	18.3
Arkansas	783	5,130	15.3
California	39,572	165,030	24.0
Colorado	4,198	25,120	16.7
Connecticut	2,289	9,560	23.9
Delaware	424	4,400	9.6
District of Columbia	5,454	12,950	42.1
Florida	33,458	125,330	26.7
Georgia	9,078	39,030	23.3
Hawaii	841	4,360	19.3
Idaho	562	4,790	11.7
Illinois	15,001	55,860	26.9
Indiana	2,919	22,170	13.2
Iowa	1,350	4,760	28.4
Kansas	863	5,060	17.1
Kentucky	1,482	12,990	11.4
Louisiana	3,349	15,920	21.0
Maine	584	3,950	14.8
Maryland	4,429	27,300	16.2
Massachusetts	8,535	24,900	34.3
Michigan	4,259	29,570	14.4
Minnesota	3,842	21,720	17.7
Mississippi	1,049	4,530	23.2
Missouri	3,260	18,370	17.7
Montana	272	2,290	11.9
Nebraska	650	2,180	29.8
Nevada	2,221	11,390	19.5
New Hampshire	568	3,020	18.8
New Jersey	5,413	25,280	21.4
New Mexico	1,151	6,800	16.9
New York	30,658	72,640	42.2
North Carolina	5,737	32,490	17.7
North Dakota	200	1,520	13.2
Ohio	6,227	40,320	15.4
Oklahoma	1,454	11,030	13.2
Oregon	3,308	19,750	16.7
Pennsylvania	9,914	36,490	27.2
Puerto Rico	358	9,700	3.7
Rhode Island	1,030	3,880	26.5
South Carolina	1,989	10,390	19.1
South Dakota	115	910	12.6
Tennessee	4,852	22,460	21.6
Texas	26,467	123,790	21.4
Utah	2,175	6,840	31.8
Vermont	287	1,060	27.1
Virginia	4,627	31,430	14.7
Washington	8,735	40,050	21.8
West Virginia	491	5,250	9.4
Wisconsin	2,271	12,980	17.5
Wyoming	86	890	9.7

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for year 2020 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated using data from IQVIA pharmacy database reported through December 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Arizona			
Maricopa County	3,456	22,720	15.2
California			
Alameda County	2,152	8,930	24.1
Los Angeles County	13,464	67,450	20.0
Orange County	1,990	10,510	18.9
Riverside County	1,719	11,080	15.5
Sacramento County	931	5,920	15.7
San Bernardino County	751	11,890	6.3
San Diego County	3,626	14,500	25.0
San Francisco County	8,639	10,840	79.7
District of Columbia	5,701	12,950	44.0
Florida			
Broward County	3,682	20,470	18.0
Duval County	496	8,970	5.5
Hillsborough County	1,370	12,910	10.6
Miami-Dade County	6,476	21,760	29.8
Orange County	2,752	15,310	18.0
Palm Beach County	874	9,170	9.5
Pinellas County	1,085	9,530	11.4
Georgia			
Cobb County	548	3,070	17.9
DeKalb County	1,522	6,290	24.2
Fulton County	3,203	13,120	24.4
Gwinnett County	674	3,240	20.8
Illinois			
Cook County	13,383	39,060	34.3
Indiana			
Marion County	1,107	9,150	12.1
Louisiana			
East Baton Rouge Parish	489	1,810	27.0
Orleans Parish	1,475	4,590	32.1
Maryland			
Baltimore City	880	6,330	13.9
Montgomery County	897	5,770	15.5
Prince George's County	789	4,040	19.5
Massachusetts			
Suffolk County	2,705	6,520	41.5
Michigan			
Wayne County	1,194	9,270	12.9
Nevada			
Clark County	1,816	11,670	15.6
New Jersey			
Essex County	672	4,090	16.4
Hudson County	1,019	4,650	21.9

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019 *(cont)*		
New York			
Bronx County	2,199	5,570	39.5
Kings County	7,319	15,650	46.8
New York County	13,583	15,540	87.4
Queens County	3,796	9,230	41.1
North Carolina			
Mecklenburg County	1,318	8,450	15.6
Ohio			
Cuyahoga County	932	7,520	12.4
Franklin County	1,986	11,620	17.1
Hamilton County	546	7,720	7.1
Pennsylvania			
Philadelphia County	3,578	9,840	36.4
Puerto Rico			
San Juan Municipio	—[d]	2,190	n/a
Tennessee			
Shelby County	630	6,450	9.8
Texas			
Bexar County	1,468	11,920	12.3
Dallas County	3,997	28,670	13.9
Harris County	4,838	40,670	11.9
Tarrant County	1,443	11,340	12.7
Travis County	4,501	11,590	38.8
Washington			
King County	6,576	17,890	36.8

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020		
Arizona			
Maricopa County	3,639	22,720	16.0
California			
Alameda County	1,912	8,930	21.4
Los Angeles County	13,901	67,450	20.6
Orange County	2,040	10,510	19.4
Riverside County	1,793	11,080	16.2
Sacramento County	898	5,920	15.2
San Bernardino County	775	11,890	6.5
San Diego County	3,520	14,500	24.3
San Francisco County	7,511	10,840	69.3
District of Columbia	5,454	12,950	42.1
Florida			
Broward County	6,512	20,470	31.8
Duval County	703	8,970	7.8
Hillsborough County	1,423	12,910	11.0
Miami-Dade County	10,075	21,760	46.3
Orange County	3,719	15,310	24.3
Palm Beach County	2,966	9,170	32.3
Pinellas County	1,130	9,530	11.9
Georgia			
Cobb County	600	3,070	19.5
DeKalb County	1,605	6,290	25.5
Fulton County	3,344	13,120	25.5
Gwinnett County	742	3,240	22.9
Illinois			
Cook County	12,162	39,060	31.1
Indiana			
Marion County	1,105	9,150	12.1
Louisiana			
East Baton Rouge Parish	493	1,810	27.2
Orleans Parish	1,230	4,590	26.8
Maryland			
Baltimore City	799	6,330	12.6
Montgomery County	851	5,770	14.7
Prince George's County	731	4,040	18.1
Massachusetts			
Suffolk County	2,560	6,520	39.3
Michigan			
Wayne County	1,131	9,270	12.2
Nevada			
Clark County	1,872	11,670	16.0
New Jersey			
Essex County	650	4,090	15.9
Hudson County	963	4,650	20.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2020, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 *(cont)*		
New York			
Bronx County	1,832	5,570	32.9
Kings County	6,611	15,650	42.2
New York County	12,253	15,540	78.8
Queens County	3,454	9,230	37.4
North Carolina			
Mecklenburg County	1,481	8,450	17.5
Ohio			
Cuyahoga County	869	7,520	11.6
Franklin County	2,126	11,620	18.3
Hamilton County	580	7,720	7.5
Pennsylvania			
Philadelphia County	3,221	9,840	32.7
Puerto Rico			
San Juan Municipio	—[d]	2,190	n/a
Tennessee			
Shelby County	772	6,450	12.0
Texas			
Bexar County	1,689	11,920	14.2
Dallas County	4,944	28,670	17.2
Harris County	5,768	40,670	14.2
Tarrant County	1,579	11,340	13.9
Travis County	4,916	11,590	42.4
Washington			
King County	6,067	17,890	33.9

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for year 2020 are preliminary and should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated using data from IQVIA pharmacy database reported through December 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019 and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Data value <40 was not reported due to unreliability.